These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. R. Michael Blaese: still blazing a path of his own. Jenks S J Natl Cancer Inst; 1998 Aug; 90(16):1188-91. PubMed ID: 9719076 [No Abstract] [Full Text] [Related]
3. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907 [TBL] [Abstract][Full Text] [Related]
4. EMA greenlights second gene therapy. Mullard A Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988 [No Abstract] [Full Text] [Related]
5. Effects of enzyme replacement therapy on immune function in ADA deficiency patient. Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173 [No Abstract] [Full Text] [Related]
6. Stem-cell treatment brings a historic week in gene therapy. Jenks S J Natl Cancer Inst; 1993 Jun; 85(12):944-6. PubMed ID: 8496979 [No Abstract] [Full Text] [Related]
7. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Blaese RM Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875 [TBL] [Abstract][Full Text] [Related]
8. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699 [TBL] [Abstract][Full Text] [Related]
13. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. Bollinger ME; Arredondo-Vega FX; Santisteban I; Schwarz K; Hershfield MS; Lederman HM N Engl J Med; 1996 May; 334(21):1367-71. PubMed ID: 8614422 [No Abstract] [Full Text] [Related]
14. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. Trotta L; Martelius T; Siitonen T; Hautala T; Hämäläinen S; Juntti H; Taskinen M; Ilander M; Andersson EI; Zavialov A; Kaustio M; Keski-Filppula R; Hershfield M; Mustjoki S; Tapiainen T; Seppänen M; Saarela J J Allergy Clin Immunol; 2018 Apr; 141(4):1534-1537.e8. PubMed ID: 29391253 [No Abstract] [Full Text] [Related]
15. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy. Misaki Y; Ezaki I; Ariga T; Kawamura N; Sakiyama Y; Yamamoto K Mol Ther; 2001 Jan; 3(1):24-7. PubMed ID: 11162307 [TBL] [Abstract][Full Text] [Related]
16. Department of Health and Human Services, Public Health Service, National Institutes of Health. Human Gene Therapy Subcommittee. Minutes of Meeting, June 1, 1990. Recomb DNA Tech Bull; 1990 Dec; 13(4):245-72. PubMed ID: 2093948 [No Abstract] [Full Text] [Related]
18. Two more cell infusions on schedule for gene replacement therapy patient. Marwick C JAMA; 1991 May; 265(18):2311-2. PubMed ID: 2016822 [No Abstract] [Full Text] [Related]
19. Progress toward human gene therapy. Miller AD Blood; 1990 Jul; 76(2):271-8. PubMed ID: 2196089 [No Abstract] [Full Text] [Related]
20. A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow. Kohn D; Wilson JM Hum Gene Ther Clin Dev; 2015 Dec; 26(4):203-7. PubMed ID: 26684443 [No Abstract] [Full Text] [Related] [Next] [New Search]